jyseleca
gilead sciences ireland uc, galapagos nv - filgotinib maleate - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
ambisome 50 mg pulver zur herstellung einer infusionslösung
haemato pharm gmbh - amphotericin b -
daunoxome 2 mg/ml, konzentrat zur herstellung einer infusionslösung
intergal pharma limited (8144431) - daunorubicinhydrochlorid - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; daunorubicinhydrochlorid (07163) 53,46 milligramm
retrovir 100mg hartkapseln
viiv healthcare b.v. (8182271) - zidovudin - hartkapsel - zidovudin (24191) 100 milligramm
retrovir i.v. 10mg/ml konzentrat zur herstellung einer infusionslösung
viiv healthcare b.v. (8182271) - zidovudin - konzentrat zur herstellung einer infusionslösung - zidovudin (24191) 200 milligramm
retrovir 250mg hartkapseln
viiv healthcare b.v. (8182271) - zidovudin - hartkapsel - zidovudin (24191) 250 milligramm
retrovir 300mg filmtabletten
viiv healthcare uk limited (8130038) - zidovudin - filmtablette - zidovudin (24191) 300 milligramm
retrovir 100mg/10ml lösung zum einnehmen
viiv healthcare b.v. (8182271) - zidovudin - lösung zum einnehmen - zidovudin (24191) 50 milligramm
tenofovirdisoproxil stada 245 mg filmtabletten
stada arzneimittel gmbh - tenofovir disoproxil succinat -
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastische mittel - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.